Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload

Publisher： John Wiley & Sons Inc

E-ISSN： 1537-2995|55|7|1613-1620

ISSN： 0041-1132

Source： TRANSFUSION, Vol.55, Iss.7, 2015-07, pp. : 1613-1620

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia

By  

TRANSFUSION, Vol. 54, Iss. 6, 2014-06 ,pp. : 1542-1551

John Wiley & Sons Inc

Access to resources Recommend Favorite

Two-Year Analysis of Efficacy and Safety of Deferasirox Treatment for Transfusional Iron Overload in Sickle Cell Anemia Patients

By  

Acta Haematologica, Vol. 128, Iss. 2, 2012-06 ,pp. : 113-118

Karger

Access to resources Recommend Favorite

CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload

By  

Oncology Research and Treatment, Vol. 39, Iss. 7-8, 2016-06 ,pp. : 424-431

Karger

Access to resources Recommend Favorite

Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 233-242

Karger

Access to resources Recommend Favorite

Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload

By  

Acta Haematologica, Vol. 138, Iss. 2, 2017-09 ,pp. : 119-128

Karger

Access to resources Recommend Favorite